Ultragenyx Pharmaceutical Inc. (RARE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on April 12, 2021. The report addresses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a disclosure of director departure and does not contain financial statements.
Material Changes
The material change disclosed is the departure of Clay B. Siegall, Ph.D., from the Board of Directors. Dr. Siegall notified the Company that he will not stand for re-election at the 2021 Annual Meeting of Stockholders. He will continue to serve as a director until the conclusion of the meeting.
Management Commentary and Risks
Management stated that Dr. Siegall's decision is for personal reasons and is not related to any disagreement with the Company regarding its operations, policies, or practices. No other risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Clay B. Siegall, Ph.D., will not seek re-election as a director at the 2021 Annual Meeting.
- The departure is attributed to personal reasons with no reported disagreement with the Company.
- Dr. Siegall remains a director until the 2021 Annual Meeting concludes.
- This filing contains no financial performance data or updated guidance.